RHHBY (RHHBY) Stock Price & Analysis
RHHBY (RHHBY) rose 1.28% to USD 54.7 as of July 25, 2026 at 01:47 UTC, according to Nexqual real-time market data.
RHHBY last closed at USD 54.01; the session ranged USD 53.89–54.84 on volume of 446,670 shares. Market capitalization is $348.66B, with a 52-week range of USD 37.51–60.85 (OQX). Source: Nexqual, July 25, 2026 at 01:47 UTC.
Key Statistics (as of July 25, 2026 at 01:47 UTC)
| Price | USD 54.7 |
|---|---|
| Change | ▲ 1.28% (up) |
| Previous Close | USD 54.01 |
| Open | USD 53.89 |
| Day Range | USD 53.89 – 54.84 |
| 52-Week Range | USD 37.51 – 60.85 |
| Volume | 446,670 shares |
| Market Cap | $348.66B |
| Exchange | OQX |
Technical Analysis (RHHBY)
Nexqual's technical model rates RHHBY "BUY" based on 5 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 01:47 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 64.59 (neutral) |
| vs SMA50 | Above (USD 51.43) |
| MACD | 0.45 (positive) |
Analyst Ratings (RHHBY)
Wall Street analysts rate RHHBY "Buy" based on 7 analysts, with a mean price target of USD 57.23 (range USD 46–67), per Nexqual as of July 25, 2026 at 01:47 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 57.23 |
| High Target | USD 67 |
| Low Target | USD 46 |
| Buy / Hold / Sell | 3 / 5 / 0 |
Earnings (RHHBY)
| Revenue Estimate | $15.42B |
|---|
Source: Nexqual, July 25, 2026 at 01:47 UTC.
Financials & Fundamentals (RHHBY)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
Source: Nexqual, July 25, 2026 at 01:47 UTC.
Financial Health Score (RHHBY)
Nexqual rates RHHBY's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 01:47 UTC.
| Growth | Mixed — Revenue +1.7% YoY (annual), slow |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Ownership (RHHBY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.54% |
| Shares Outstanding | 5.52B |
Source: Nexqual, July 25, 2026 at 01:47 UTC.
Leadership (RHHBY)
RHHBY is led by Thomas Schinecker (age 50), Group Chief Executive Officer, per Nexqual as of July 25, 2026 at 01:47 UTC.
| Group Chief Executive Officer | Thomas Schinecker (age 50) |
|---|---|
| Executive Chairman | Severin Schwan (age 58) |
| Chief Financial Officer | Alan Hippe (age 58) |
Major Backers & Investors (RHHBY)
Notable institutional backers of RHHBY include Dodge & Cox Funds-Dodge & Cox Stock Fund, according to Nexqual as of July 25, 2026 at 01:47 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 0.24% |
Source: Nexqual, July 25, 2026 at 01:47 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NVS | Novartis AG | USD 155.01 | ▲ 1.26% |
| SNY | Sanofi | USD 43.35 | ▼ 1% |
| NSRGY | Nestle S.A. | USD 98.36 | ▼ 5.51% |
| AZN | AstraZeneca PLC | USD 169.26 | ▼ 0.28% |
| GSK | GSK plc | USD 51.35 | ▲ 1.16% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:47 UTC. This page is informational and not investment advice.